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Abstract: ING1 has regulatory roles in the expression of genes associated with proliferation, apoptosis, and senescence. p33(ING1b) is
the most widely expressed isoform of the gene. Downregulation of its nuclear expression is involved in differentiation and pathogenesis
in invasive breast carcinoma. Yet the mechanism(s) by which p33 nuclear targeting is regulated remains unknown. In this study, we
analyzed human invasive breast carcinoma tissue samples by immunostaining with p33 and correlating p33 location with the presence
of ERα. Our findings show the expression of p33 protein in ERα-positive tumor samples was in the nucleus alone, while the expression
was mainly in the cytoplasm in ERα-negative tumor samples. Examination of the localization of p33 in the nucleus and/or cytoplasm
in several different cell lines demonstrated 17β-estradiol (E2) treatment causes dramatic compartmental shift in p33 protein from the
cytoplasm to the nucleus in ERα-positive MDA-66 cells. No significant differences in ERα-negative MDA-MB-231 cells in the same
conditions were observed. We show for the first time nuclear localization of p33 is regulated by estradiol induction in ERα-positive
breast cancer cells. These results suggest compartmental shift in p33 by ER signaling may be an important molecular event in the
differentiation and pathogenesis of invasive breast cancer.
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1. Introduction
ING1 is a type II tumor suppressor that affects cell growth,
apoptosis, and senescence by altering chromatin structure and
regulates transcription (Garkavtsev et al., 1996; Russell et al.,
2006; Coles and Jones, 2009; Li et al., 2011). The most widely
expressed ING1 isoform is p33(ING1b) and downregulation
of nuclear p33(ING1b) expression was associated with more
poorly differentiated tumors in invasive breast carcinoma
(Nouman et al., 2003a). Furthermore, it has been shown that
the transfer of p33(ING1b) protein from the nucleus to the
cytoplasm may result in the loss of normal cellular function
of the protein. This might play a role in tumorigenesis and
lymph node metastasis of oral squamous cell carcinomas as
well as esophageal squamous cell carcinoma (Zhang et al.,
2008; Zhu et al., 2012). Several studies showed that nuclear
import of p33(ING1b) occurs concomitantly with physical
and/or functional interactions with a subset of nuclear
proteins, including p53, p300/CBP, and HDAC1 in different
models. However, little is known about the way and the
importance of nuclear localization (Feng et al., 2002; Kataoka
* Correspondence: esra.erdal@deu.edu.tr

et al., 2003; Nouman et al., 2003b). p33(ING1b) may also
have a role in estrogen-dependent signaling in mammalian
cells. It was shown that p33(ING1b) interacts directly with
the activation function 2 (AF2) domain of estrogen receptor
α (ERα) and modulates the transcriptional activity of an E2responsive reporter construct in a dose-dependent manner
as well (Toyama et al., 2003). ING1 might help and/or
contribute to the regulation of ERα-dependent target gene
expression through the facilitation of a localized relaxation
in chromatin compaction surrounding ERα-responsive
genes and it might have a role in the development of breast
cancers (Margueron et al., 2004; Doyon et al., 2006).
Therefore, it is critical to explain how the nuclear
export of p33(ING1b) is regulated in ER signaling.
In the present study, we firstly demonstrated an
abundant nuclear localization of p33(ING1b) in ERα
expressing human invasive breast carcinoma tissues.
Then we showed 17β-estrodiol (E2) induction enhanced
localization of p33(ING1b) into the nucleus in ER
α-positive breast cancer cell lines in vitro.
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2. Materials and methods
2.1. Cell lines and culture
Human breast adenocarcinoma cell lines, MDA-MB-231
(ERα negative) and MDA-66 (ERα-positive), were used in
this study. MDA-66 was produced by stable transfection of
MDA-MB-231 with human ER expression vector (pCMVERα) (Alotaibi et al., 2006).
Both cell lines were maintained in high glucose
Dulbecco’s modified Eagle’s medium [Gibco, (CA, USA)
supplemented with 10% fetal bovine serum (FBS), 1%
penicillin/streptomycin (P/S), and 1% L-glutamine
(Biochrom, Berlin, Germany)] at 37 °C in a 5% CO2
incubator. MDA-66 was maintained in the above medium
with the addition of 0.4 mg/mL hygromycin (Roche,
Penzberg Germany). In general, hormone induction
experiments were performed in sf-DMEM (a phenol
red-free DMEM supplemented with 10% dextran-coatedcharcoal stripped FBS, 1% P/S, and 1% L-glutamine)
unless otherwise mentioned. Two days before the addition
of hormone, cells were fed with sf-DMEM in order to
deplete the culture media from endogenous steroids and
retinoids. E2 was applied to a final concentration of 10 nM
for 3 h.
2.2. Patients and tissues
The patients studied comprised a series of 93 women with
invasive breast carcinoma of mean age 54, ranging from 32
to 65 years. These patients were diagnosed at the Hospital
of the Medical School of Dokuz Eylül University, İzmir,
Turkey, between 1991 and 2006. Routinely processed,
formalin fixed, paraffin wax embedded blocks were
retrieved from the archives. The Ethics Committee of
Dokuz Eylül University Medical School approved the
study.
2.3. Immunostaining
Five-micrometer-thick sections from the paraffinembedded formalin-fixed blocks were used for
immunostaining following deparaffinization with xylene/
alcohol and were subjected to antigen retrieval using a
microwave in Tris-EDTA buffer (pH 8.0) for 20 min.
Mouse monoclonal anti-p33 (ING1b) antibody (Clone
15B9 produced by Dr R Çetin Atalay) was used with 1:5
dilution as followed in the Dako EnVision + Dual (DAKO,
Denmark) method according to the manufacturer’s
instructions. This antibody has been tested for its specificity
in different cell lines (Sayan et al., 2009). The signals were
detected using diaminobenzidine (DAB) staining after the
specimens were counterstained with hematoxylin. For the
staining of adherent cells grown on coverslips, the same
protocol starting with primary antibody incubation was
followed after methanol fixation and blocking with 5%
fetal calf serum (FCS) in phosphate-buffered saline (PBS).
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For immunofluorescence staining of cells grown on
coverslips, cells were fixed by 4% paraformaldehyde (PFA)
for 15 min and permeabilized using 0.25% Triton X-100
for 10 min. Nonspecific protein binding was blocked
by incubation with 10% FCS for 30 min in PBS at room
temperature (RT). Cells were then incubated with both
mouse monoclonal anti-p33(ING1b) antibody (1:10) and
rabbit polyclonal anti-ERα antibody (Millipore 06-935)
(1:50) together in PBS containing 0.25% Triton X-100
(PBS-T) and 3% FCS for 2 h at RT. After washing three times
with PBS-T for 30 min, cells were further incubated with
goat anti-mouse IgG antibody, (H + L) FITC conjugated
(Millipore AP124F) (1:2000) and goat anti-rabbit IgG
antibody, rhodamine conjugated (Millipore AP132R)
(1:2000) for 1 h at RT. Counterstaining was performed
by DAPI staining (1:500) for 5 min. After the slides were
mounted using fluorescence-mounting medium (Dako),
they were examined using an Olympus BX61 fluorescence
microscope.
2.4. Scoring
The intensities of nuclear and cytoplasmic staining for
p33ING1b on the cells were assessed on a four-point scale
as follows: (0) for 0%–25%; (+) for 26%-50%; (++) for
51%–75%, and (+++) for 76%–100%. This scoring system
was used for all proteins studied.
2.5. Western blotting
Cells were washed and scraped with ice-cold PBS on
ice and centrifuged at 5000 rpm for 5 min. A ProteoJET
Cytoplasmic and Nuclear Protein Extraction Kit
(Fermentas K0311) was used to extract protein according
to the manufacturer’s instructions.
Protein concentration was determined by BCA assay
under the manufacturer’s instructions (Pierce 23225). The
proteins were then resolved by sodium dodecyl sulfate
polyacrylamide gel electrophoresis (SDS-PAGE) and
transferred to PVDF membrane (Roche 03010040001,
Mannheim Germany). The membrane was blocked with
nonfat milk and immunoblotted with anti- p33(ING1b)
antibody (1:100) and anti-ERα antibody (Millipore 06935) (1:500), separately. The unbound antibody was
washed with TBS-T and the membrane was incubated
with horseradish peroxidase-conjugated secondary
antibody (Pierce 32430, 32460) and Super Signal West
Dura Extended Duration Substrate (Pierce 34076) was
used for detection. Mouse monoclonal anti-PCNA (PC10)
antibody (Abcam ab29) (1:500) and rabbit polyclonal antiCalnexin (H-70) antibody (Santa Cruz-11397) (1:1000)
were used as loading controls for nuclear and cytoplasmic
fractions, respectively.
2.6. Statistical analysis
To assess the relations between nuclear and/or cytoplasmic
p33ING1b and ERα expression in tumor tissues the chisquare statistical test was applied by using SPSS.
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3. Results
3.1. Subcellular expression of p33(ING1b) in invasive
ductal breast carcinoma tissues
Ninety-three invasive breast carcinoma tissues were
analyzed for the presence of ERα and for the localization
of p33(ING1b). The tumor tissue series used in this study
comprised 53 cases of invasive ductal carcinomas, 19
invasive lobular carcinomas, 9 medullary carcinomas,
and 4 papillary, 5 metastatic, and 3 mucinous breast
carcinomas.
Among the 93 cases studied, p33(ING1b) staining in
either the nuclear or cytoplasmic part of the tumor was
seen in 63 samples (68%), while 29 out of the 93 samples
(31%) showed staining in both compartments. Only one
case (1%) did not show p33(INGb) staining in either the
cytoplasm or in the nucleus. Figure 1 shows an example for
strong p33(INGb) expression in the nucleus or cytoplasm
of a tumor cell.
3.2. Increased nuclear expression of p33(ING1b) in
estrogen receptor alpha positive breast carcinoma
sections
In order to determine whether there is a correlation
between p33(ING1b) localization and ERα expression,

subcellular localization of p33(ING1b) expression was
compared between ERα-positive and ERα-negative breast
tumor sections (Table 1). Based on immunohistochemical
staining data, cytoplasmic expression of p33(ING1b) was
statistically more evident in ERα-negative sections, while
a striking shift to nuclear expression was observed in
ERα expressing tumors. These results indicated that ERα
expression in invasive breast carcinoma might influence
a shift in the localization of p33(ING1b) towards the
nucleus. Furthermore, when intensities of p33(ING1b)
staining were analyzed in these tissues, no significance
difference was observed (data not shown).
3.3. Estradiol activated ERα promotes nuclear
localization of p33 (ING1b) in breast carcinoma cell line
To further study the effect of ERα on the subcellular
localization of p33(ING1b) in breast carcinoma cells,
we carried out immunostaining experiments using
p33(ING1b) antibody in MDA-MB-231, an ERα negative
breast adenocarcinoma cell line, and its stable clone
ectopically expressing ERα and MDA-66 cells. Under
steroid-free conditions p33(ING1b) expression was more
abundant in the cytoplasm of MDA-MB-231 as well as
MDA-66 (Figure 2). However, treatment with 17β-estradiol

× 100

× 100
(B)

(A)

Figure 1. Positive p33(ING1b) immunohistochemical staining. (A) Invasive lobular breast carcinoma tissue strongly expressing
p33(ING1b) only in the nuclei of tumor cells. (B) Invasive ductal breast carcinoma tissue strongly expressing p33(ING1b) in the
cytoplasm of tumor cells.
Table 1. Relationship between compartmental p33(ING1b) expression and ERα expressions in
invasive breast carcinoma.
p33(ING1b) expression

ERα (–) (number of cases)

ERα (+) (number of cases)

Only in cytoplasm

22

10

In cytoplasm and nucleus

13

16

Only in nucleus

4

27

ND

1

-

*P < 0.001, ND = Not determined
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(E2) caused a significant increase in the percentage of cells
with nuclear staining only in the ERα-expressing cells
(MDA-66) compared to the ERα-negative ones (MDAMB-231) (Figure 2). We further analyzed approximately
300 cells in each condition to determine the percentage
of cells expressing p33(ING1b) in the cytoplasm only,
cytoplasm/nuclear, and nuclear only among the cells under
estradiol induction as well as control in both cell lines.
The results revealed that 17β-estradiol induction (E2) on
ERα-positive cells caused a significant shift in p33(ING1)
localization from the cytoplasm to the nucleus while it did
not have an effect on the ERα negative cells (Table 2).
In order to analyze the changes in the subcellular
localization of p33(ING1b) in the breast carcinoma cell
lines under the effect of 17β-estradiol (E2) by using
another method, we also performed immunoblotting
analysis using nuclear and cytoplasmic cell extracts
(A)

Control

(B)

after E2 induction by the conditions described before
in both MDA-MB-231 and MDA-66 cell lines. We
found that 17β-estradiol (E2) induction caused increase
in p33(ING1b) expression in nuclear lysate as well as
a decrease in cytoplasmic lysate in an ERα-positive
cell line, MDA-66. However, it did not significantly
affect p33(ING1b) expression in both compartments
of an ERα-negative cell line, MDA-MB-231 (Figure
3A). 17β-Estradiol (E2) enhanced the expression of
p33(ING1b) in the nuclear compartment 1.76-fold and
decreased the expression of p33(ING1b) 20-fold in the
cytoplasmic compartment (Figure 3B).
To evaluate the co-localization of both ERα and
p33(ING1b) in the nucleus, immunofluorescence staining
was carried out in MDA-66 cells under the effect of
17β-estradiol (E2). The number of ERα-positive cells
MDA - 66

(+) E2

MDA - MB -231

Control

(+) E2

Figure 2. p33(ING1b) expression with 17β-estradiol induction. (A) Nuclear staining of p33(ING1b) in ERα-positive MDA-66 cells.
(B) Cytoplasmic staining of p33(ING1b) in ERα-negative MDA-MB-231 cells. (Experiments were carried out in triplicate. All figures
have 40× magnification).
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Table 2. Subcellular localization of p33(ING1b) expression with stable expression of ERα in MDA-MB-231 cells
in ligand-dependent or nondependent manner.
ERα (–) cell

ERα (+) cell

MDA-MB-231

MDA-66

E2* (+)

E2 (–)

E2* (+)

E2 (–)

Cytoplasmic

24 ± 2

31 ± 4

10 ± 2

62 ± 7

Cyto./nuc.

71 ± 4

62 ± 3

61 ± 4

30 ± 4

Nuclear

5±3

5±2

29 ± 3

2±1

p33(ING1b) negative (%)

0

2±2

0

6±2

p33(ING1b) positive (%)

* 10 nM 17β-estradiol induction for 3 h in sf-DMEM medium

with p33(ING1b) in the nucleus and/or cytoplasm was
analyzed (Figure 4A). After 17β-estradiol (E2) induction
in the MDA-66 cell line, the number of cells with nuclear
MDA- MB - 231

(A)

+

-

E2

p33(ING1b) increased 10-fold, while the number of cells
with cytoplasmic p33(ING1b) did not change significantly
(Figure 4B).

MDA - 66
+

-

p33 (ING1b)
cytoplasmic

Calnexin

p33 (ING1b)
nuclear
PCNA

MDA-MB-231
1

1

MDA-66
1

0.8
0.6
0.4
0.2

0.05

0

E2

MDA-MB-231

MDA-66

2

1.76

1.6
Fold change

1
Fold change

p33 (ING1b) cytoplasmic

1.2

p33 (ING1b) nuclear

(B)

1.2

1

1.14

1

0.8
0.4
0

-

+

-

+

E2

-

+

-

+

Figure 3. (A) Expression of p33(ING1b) in nuclear and cytoplasmic compartments of cells in both ERα-positive and ERαnegative cell lines, MDA-MB-231 and MDA-66, respectively. (B) Density analysis of p33(ING1b) bands normalized with
equal loading controls at both cytoplasmic and nuclear fraction.
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ERα

(A)

P33(ING1b)
× 40

× 40

× 40

× 40

merge
× 40

× 40

(B)

Figure 4. Co-localization of ERα and p33(ING1b) expression in MDA-66 cells. (A) Representative pictures for ERα and p33(ING1b)
expression (upper line: arrows indicate the cells with both ERα and p33(ING1b) expression in nucleus; lower line: arrows indicate the
cell with nuclear ERα and cytoplasmic p33(ING1b) expression). (B) Fold change in the number of cells with nuclear ERα having nuclear
and/or cytoplasmic p33(ING1b) under the effect of 17β-estrodiol (E2) induction of MDA-66 cells.
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4. Discussion
Although ING1 has initially been identified as a tumor
suppressor gene, mutations in ING1 appear to be extremely
rare in breast carcinomas, ovarian carcinomas, colorectal
carcinomas, squamous cell carcinoma of different origins,
and melanoma (Garkavtsev et al., 1996; Nouman et al.,
2003b). Recently, the loss of nuclear ING expression has
been described in several human cancers, suggesting that
it may have a role in abrogation of ING function during
carcinogenesis (Zhang et al., 2008; Nouman et al., 2002a,
2002b; Zhu et al., 2013). Nouman et al. showed that
nuclear expression of p33(ING1b) was downregulated in
invasive carcinoma of the breast and this alteration was
significantly associated with more poorly differentiated
tumors (Nouman et al., 2003a). They also reported a
similar positive correlation between p33(ING1b) nuclear
expression and ERα expression similar to what we have
seen in the present study. This correlation is consistent with
a function for nuclear ING proteins in directing towards a
particular cellular fate under the effect of ERα signaling
through interactions with functional proteins, such as
HATs and HDACs. p33(ING1b) was shown to interact
directly with the activation function 2 (AF2) domain of
ERα and to modulate the transcriptional activity of an
ERα-responsive reporter construct in a dose-dependent
manner (Toyama et al., 2003). This also indicates a role
of nuclear p33(ING1b) in estrogen-responsive signaling
in mammalian cells. Interestingly, ectopic expression
of p33(ING1b) protein in cancer cells has a function
in DNA repair under DNA damage inducing stress in a
p53-dependent or independent manner as in fibroblasts
(Mobley and Brueggemeier, 2004; Kuo et al., 2007). It

has also been shown that DNA damage is also induced
by estrogen and/or estrogen metabolites with an ERdependent manner in breast carcinoma cell lines (Mobley
and Brueggemeier, 2004; Bianco et al., 2016). Detoxifying
enzyme activity markedly decreases with treatment with
17β-estradiol (E2) in MCF-7 cells (ER-positive), leading to
increased susceptibility of cells to oxidative DNA damage.
However, E2 has no effect on detoxifying enzyme activity
in MDA-MB-231 (ER negative) cells (Iso et al., 2006). With
regard to the established interval for E2 concentration in
these reports, it is possible to conclude that E2 might cause
DNA damage inducing stress in ERα-positive MDA-66
isogenic clone, but not in ERα negative MDA-MB-231;
then p33(ING1b) goes to the nucleus for its function in
repair.
In the present study, we established a correlation
between ERα expression and the nuclear localization of
p33(ING1b) in a variety of breast cancers samples. We also
clearly showed that nuclear localization of p33(ING1b)
is regulated by 17β-estradiol (E2) in ERα-positive breast
carcinoma cells. The mechanism demonstrated in the
present study regarding the p33(INGb) protein shift
from cytoplasm to nucleus in ERα-positive tumors in
a hormone-mediated manner could help us to develop
novel strategies for the diagnosis and treatment of invasive
breast carcinomas.
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